{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:43:34Z","timestamp":1791359014314,"version":"4.3.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hematopoietic stem cell transplant (HSCT) is potentially curative for a wide variety of malignant diseases, including acute and leukemias, lymphoma, and myelodysplasia. Choice of a stem cell donor is dependent on donor availability, donor compatibility and health, recipient disease type, and recipient condition. Current sources of stem cell donation for HSCT are matched sibling donors (MSDs), matched unrelated donors (MUDs), 1-antigen mismatched unrelated donors (MMUDs), haploidentical donors (haplo), and umbilical cord blood (UCB) units. Historically, preferred donors for HSCT have been human leukocyte antigen (HLA)-matched sibling donors; however, only about 30% of U.S. patients will have a MSD available. The majority of patients referred for HSCT will require an alternative donor graft: MUD, MMUD, UCB, or haplo. The likelihood of finding a MUD varies depending on the ethnicity of the recipient. White Caucasians of European descent have the greatest chance of finding a MUD. Chances of finding a MUD are significantly less for African-American or Hispanic recipients due to HLA polymorphisms. Therefore, MMUD, UCB, and haplo donor graft sources expand the donor pool for recipients who do not have a MSD or MUD available. Given the variety of different donor stem cell sources available today, nearly every patient who needs an allogeneic HSCT has a potential donor in 2017. All transplant-eligible patients with hematologic malignancies should be evaluated by a transplant center to determine if HSCT is a viable treatment option for their underlying disease process.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0009","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T01:00:22Z","timestamp":1495760422000},"page":"1125-1134","source":"Crossref","is-referenced-by-count":24,"title":["Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!"],"prefix":"10.1093","volume":"22","author":[{"given":"Tamila L.","family":"Kindwall-Keller","sequence":"first","affiliation":[{"name":"Department of Medicine University of Virginia School of Medicine, and Stem Cell Transplant Program, University of Virginia Cancer Center, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen K.","family":"Ballen","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Virginia School of Medicine, and Stem Cell Transplant Program, University of Virginia Cancer Center, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"2021122508221598000_onco12165-bib-0001","author":"D'Souza","year":"2017"},{"key":"2021122508221598000_onco12165-bib-0002","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0003","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","article-title":"Immunological reconstitution of sex-linked lymphopenic immunological deficiency","volume":"2","author":"Gatti","year":"1968","journal-title":"Lancet"},{"key":"2021122508221598000_onco12165-bib-0004","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA Match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122508221598000_onco12165-bib-0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2014.10.002","article-title":"8\/8 and 10\/10 high-resolution match rate for the Be the Match unrelated donor registry","volume":"21","author":"Dehn","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0006","year":"2017"},{"key":"2021122508221598000_onco12165-bib-0007","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bbmt.2015.12.012","article-title":"High-resolution match rate of 7\/8 and 9\/10 or better for the Be the Match unrelated donor registry","volume":"22","author":"Buck","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0008","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122508221598000_onco12165-bib-0009","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","article-title":"Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia","volume":"119","author":"Saber","year":"2012","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0010","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0011","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbmt.2010.09.012","article-title":"HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation","volume":"17","author":"Woolfrey","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0012","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1182\/blood-2013-04-496778","article-title":"Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)","volume":"122","author":"Saber","year":"2013","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0013","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bbmt.2015.05.028","article-title":"HLA mismatch is associated with worse outcomes after unrelated donor reduced-intensity conditioning hematopoietic cell transplantation: An analysis from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Verneris","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0014","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2004-03-0803","article-title":"Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome","volume":"104","author":"Flomenberg","year":"2004","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0015","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1200\/JCO.2006.08.0952","article-title":"Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10\/10) in patients with standard-risk hematologic malignancy: A prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy","volume":"24","author":"Yakoub-Agha","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122508221598000_onco12165-bib-0016","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood.V81.4.1094.1094","article-title":"Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?","volume":"81","author":"Ringden","year":"1993","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0017","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood.V88.9.3634.bloodjournal8893634","article-title":"FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors","volume":"88","author":"Nash","year":"1996","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0018","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: A randomized, open-label, multicenter phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122508221598000_onco12165-bib-0019","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haematopoietic cell transplantation from unrelated donors: A randomized, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122508221598000_onco12165-bib-0020","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122508221598000_onco12165-bib-0021","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.bbmt.2006.07.004","article-title":"Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning","volume":"12","author":"Baron","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0022","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122508221598000_onco12165-bib-0023","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/bmt.2013.14","article-title":"Donor choice according to age for allo-SCT for AML in complete remission","volume":"48","author":"Ayuk","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0024","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.exphem.2008.03.011","article-title":"Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors","volume":"36","author":"Ayuk","year":"2008","journal-title":"Exp Hematol"},{"key":"2021122508221598000_onco12165-bib-0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/10428194.2014.930851","article-title":"Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant","volume":"56","author":"Ceberio","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2021122508221598000_onco12165-bib-0026","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122508221598000_onco12165-bib-0027","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"key":"2021122508221598000_onco12165-bib-0028","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"key":"2021122508221598000_onco12165-bib-0029","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1056\/NEJM198910263211707","article-title":"Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling","volume":"321","author":"Gluckman","year":"1989","journal-title":"N Engl J Med"},{"key":"2021122508221598000_onco12165-bib-0030","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2012-08-449108","article-title":"Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia","volume":"121","author":"Scaradavou","year":"2013","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0031","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.exphem.2013.05.297","article-title":"Double umbilical cord blood transplantation for hematologic malignancies: A long-term analysis from the SFGM-TC registry","volume":"41","author":"Wallet","year":"2013","journal-title":"Exp Hematol"},{"key":"2021122508221598000_onco12165-bib-0032","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1405584","article-title":"One-unit versus two-unit cord-blood transplantation for hematologic cancers","volume":"371","author":"Wagner","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122508221598000_onco12165-bib-0033","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.bbmt.2005.02.004","article-title":"Serious infections after unrelated donor transplantation in 136 children: Impact of stem cell source","volume":"11","author":"Barker","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0034","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3324\/haematol.2015.127787","article-title":"Better allele-level matching improves transplant-related mortality after double cord blood transplantation","volume":"100","author":"Oran","year":"2015","journal-title":"Haematologica"},{"key":"2021122508221598000_onco12165-bib-0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2013-05-506253","article-title":"Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation","volume":"123","author":"Eapen","year":"2014","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0036","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122508221598000_onco12165-bib-0037","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bbmt.2014.10.030","article-title":"Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: Similar outcomes regardless of donor type","volume":"21","author":"Warlick","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0038","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bbmt.2014.11.685","article-title":"Comparison of cord blood transplantation with unrelated bone marrow transplantation in patients older than fifty years","volume":"21","author":"Tanaka","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0039","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.bbmt.2014.02.020","article-title":"Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: A Center for International Blood and Marrow Transplant Research-Eurocord analysis","volume":"20","author":"Weisdorf","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbmt.2014.11.675","article-title":"Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: A collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party","volume":"21","author":"Robin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0041","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2015.02.014","article-title":"Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: A study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"21","author":"Malard","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0042","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2011.10.016","article-title":"Reduced-intensity conditioning stem cell transplantation: Comparison of double umbilical cord blood and unrelated donor grafts","volume":"18","author":"Chen","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0043","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2011-12-400630","article-title":"Reduced-intensity conditioning transplantation in acute leukemia: The effect of source of unrelated donor stem cells on outcomes","volume":"119","author":"Brunstein","year":"2012","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0044","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.bbmt.2014.07.021","article-title":"Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: Comparison among alternative graft sources","volume":"20","author":"Ballen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0045","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1207285","article-title":"Cord-blood engraftment with ex vivo mesenchymal-cell coculture","volume":"367","author":"Lima","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122508221598000_onco12165-bib-0046","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nm.2080","article-title":"Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution","volume":"16","author":"Delaney","year":"2010","journal-title":"Nature Med"},{"key":"2021122508221598000_onco12165-bib-0047","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1172\/JCI74556","article-title":"Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment","volume":"124","author":"Horwitz","year":"2014","journal-title":"J Clin Invest"},{"key":"2021122508221598000_onco12165-bib-0048","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood-2013-05-503177","article-title":"Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0049","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1470-2045(08)70180-3","article-title":"Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: A phase I\/II study","volume":"9","author":"Frassoni","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021122508221598000_onco12165-bib-0050","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1182\/blood-2015-01-607366","article-title":"Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation","volume":"125","author":"Popat","year":"2015","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0051","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1089\/scd.2012.0636","article-title":"In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematologic malignancies","volume":"22","author":"Farag","year":"2013","journal-title":"Stem Cells Dev"},{"key":"2021122508221598000_onco12165-bib-0052","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood-2016-05-715292","article-title":"Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation","volume":"128","author":"Aljitawi","year":"2016","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0053","article-title":"Stem-Ex (copper chelation based) ex vivo expanded cord blood umbilical cord blood stem cell transplantation (UCBT) accelerates engraftment and improves 100 day survival in myeloablated patients compared to a registry cohort undergoing double-unit UCBT: Results of a multicenter study of 101 patients with hematologic malignancies","author":"Montesinos","year":"2013","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0054","article-title":"Double-unit cord blood (CB) transplantation combined with haplo-identical CD34+ selected PBSC results in 100% CB engraftment and enhanced myeloid recovery","author":"Ponce","year":"2013","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0055","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"2021122508221598000_onco12165-bib-0056","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2011.28","article-title":"In vivo B-cell depletion with rituximab for alternative donor hematopoietic SCT","volume":"47","author":"Dominietto","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0057","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2004.08.016","article-title":"Graft engineering for allogeneic haploidentical stem cell transplantation","volume":"33","author":"Tabilio","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"2021122508221598000_onco12165-bib-0058","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0059","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.bbmt.2016.08.003","article-title":"Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematologic malignancies","volume":"22","author":"Baker","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0060","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0061","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.bbmt.2016.05.010","article-title":"Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: A retrospective single-center review","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0062","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.bbmt.2016.07.010","article-title":"Impact of donor type on outcome after allogeneic hematopoietic cell transplantation for acute leukemia","volume":"22","author":"Solomon","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0063","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbmt.2015.09.002","article-title":"Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-Identical sibling donors: A multivariable analysis including disease risk index","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0064","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122508221598000_onco12165-bib-0065","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","article-title":"Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen-matched unrelated and related donors","volume":"20","author":"Stasi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0066","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2015.98","article-title":"Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia","volume":"29","author":"Ruggeri","year":"2015","journal-title":"Leukemia"},{"key":"2021122508221598000_onco12165-bib-0067","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0068","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"2021122508221598000_onco12165-bib-0069","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br J Haematol"},{"key":"2021122508221598000_onco12165-bib-0070","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.bbmt.2016.08.021","article-title":"Strategies and challenges for pharmacologic maintenance therapies after allogeneic hematopoietic cell transplantation","volume":"22","author":"DeFilipp","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0071","article-title":". Multicenter open-label Phase 1b\/2 study of ibrutinib in steroid dependent\/refractory chronic graft versus host disease (cGVHD)","volume":"51","author":"Miklos","journal-title":"Bone Marrow Transplant"},{"key":"2021122508221598000_onco12165-bib-0072","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: A multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0009","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/9\/1125\/41916244\/oncolo_22_9_1125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/9\/1125\/41916244\/oncolo_22_9_1125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:23:16Z","timestamp":1640420596000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/9\/1125\/6444563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":72,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,5,25]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0009","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9,1]]},"published":{"date-parts":[[2017,5,25]]}}}